Proteomic Serum Biomarkers and Their Potential Application in Cancer Screening Programs

International Journal of Molecular Sciences

Anouck Huijbers¹  Berit Velstra¹  Tim J. A. Dekker¹  Wilma E. Mesker¹  Yuri E. M. van der Burgt²  Bart J. Mertens³  André M. Deelder² 

[1]Department of Surgery, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands

[2] E-Mails:

[3]Department of Parasitology, Biomolecular Mass Spectrometry Unit, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands

[4]Department of Medical Statistics, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands

关键词: mass spectrometry;    biomarker;    MALDI-TOF;    SELDI-TOF;    colorectal cancer;    breast cancer;    screening;    proteomics;    magnetic beads;   

DOI  :  10.3390/ijms11114175

来源: mdpi

【 摘 要 】

Early diagnosis of cancer is of pivotal importance to reduce disease-related mortality. There is great need for non-invasive screening methods, yet current screening protocols have limited sensitivity and specificity. The use of serum biomarkers to discriminate cancer patients from healthy persons might be a tool to improve screening programs. Mass spectrometry based proteomics is widely applied as a technology for mapping and identifying peptides and proteins in body fluids. One commonly used approach in proteomics is peptide and protein profiling. Here, we present an overview of profiling methods that have the potential for implementation in a clinical setting and in national screening programs.

【 授权许可】

CC BY   
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.